论文部分内容阅读
[目的]探讨小细胞肺癌(SCLC)组织中CD151的表达水平及其临床意义。[方法]免疫组化SP法检测82例SCLC组织与20例癌旁组织中CD151的表达情况,并结合临床资料进行分析。[结果]SCLC组织中CD151阳性表达率明显高于癌旁肺组织(χ2=22.274,P=0.034)。CD151蛋白表达与SCLC患者年龄、性别、是否吸烟等无明显相关性(P>0.05),局限期与广泛期的阳性表达率之间没有明显差异(χ2=0.113,P=0.737),但局限期与广泛期SCLC组织中CD151的阳性表达率均高于癌旁组织(χ2分别为11.123、14.391,P分别为0.001、0.000)。CD151阴性表达的患者1年生存率明显高于阳性表达者(χ2=5.637,P=0.018)。Kaplan-Meier分析提示CD151阴性表达者生存期显著高于阳性表达者(χ2=20.584,P=0.000)。[结论 ]CD151的阳性表达可能与SCLC的发生及早期转移有关;CD151的检测可用于对SCLC患者生存时间的评估,可能会成为预估其预后的一项重要指标。
[Objective] To investigate the expression of CD151 in small cell lung cancer (SCLC) and its clinical significance. [Method] The expression of CD151 in 82 cases of SCLC tissues and 20 cases of paracancerous tissues was detected by immunohistochemical SP method and analyzed with clinical data. [Results] The positive rate of CD151 expression in SCLC tissues was significantly higher than that in adjacent lung tissues (χ2 = 22.274, P = 0.034). There was no significant correlation between the expression of CD151 protein and the age, sex and smoking status of SCLC patients (χ2 = 0.113, P = 0.737), but there was no significant difference between the two groups The positive rate of CD151 in extensive SCLC tissues was higher than that in paracancerous tissues (χ2 = 11.123 and 14.391, respectively, P = 0.001,0.000, respectively). The 1-year survival rate of patients with CD151 negative expression was significantly higher than that of positive patients (χ2 = 5.637, P = 0.018). Kaplan-Meier analysis showed that the survival of CD151 negative patients was significantly higher than that of positive ones (χ2 = 20.584, P = 0.000). [Conclusion] The positive expression of CD151 may be related to the occurrence and early metastasis of SCLC. The detection of CD151 can be used to evaluate the survival time of patients with SCLC, which may be an important index to predict the prognosis.